GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

Impact · against what's priced in

The article provides no material catalyst for Eli Lilly, as the validation of 5-MEO-DMT is a peripheral pipeline detail compared to the company's GLP-1 drivers. GH Research remains a speculative play dependent on Phase III data, with cash reserves and dilution risks already factored into its current valuation.

LLY+0.00: Doesn't touch the price's assumptions
The price assumes: The next-generation pipeline, specifically retatrutide's potential
The acquisition of AtaiBeckley validates 5-MEO-DMT, but this is a niche asset that does not move the needle on the primary growth drivers or the unpriced potential of retatrutide.
What LLY's price assumes · Sep 10

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

biotech▲19%
healthcare▲2%
LLY
clinical trials
depression
dilution
fda approval
phase iii

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

What matters in this story

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

What matters in this story

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

How each ticker is affected

Connected tickers

Track these names every morning.

Medpace: 3 Key Takeaways for Long-Term Investors

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

BeOne Medicines: Brukinsa And Tevimbra Face A High Bar

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

What matters in this story

Next reads from the same story arc

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

What matters in this story

Next reads from the same story arc

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

How each ticker is affected

Connected tickers

Track these names every morning.

Medpace: 3 Key Takeaways for Long-Term Investors

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

BeOne Medicines: Brukinsa And Tevimbra Face A High Bar

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case